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The phosphodiesterase type 5 (PDE-5) inhibitors are effective in treating erectile dysfunction (ED).
ED and heart failure (HF) share similar risk factors, and commonly present together. This
association has led to questions ranging from the safety and efficacy of PDE-5 inhibitors in HF
patients to a possible role for this class of medication to treat HF patients with or without ED. In
addition to endothelial dysfunction, there are causes of ED specific to patients with HF including
low exercise tolerance, depression and HF medications. Before treating HF patients with PDE-5
inhibitors, patients should be assessed for their risk of a cardiac event during sexual activity. PDE-5
inhibitors are safe and effective in treating ED in HF patients. An improvement in erectile function
by PDE-5 inhibitors was associated with an improvement in quality of life and reduction in
depression. Several studies demonstrated the effect of PDE-5 inhibitors on HF per se. PDE-5
inhibitors improved endothelial dysfunction, increased exercise tolerance, decreased pulmonary
vascular resistance and pulmonary artery pressure, and increased cardiac index. Several
mechanisms whereby PDE-5 inhibitors improve HF have been proposed. PDE-5 inhibitors already
have a role in treating primary pulmonary hypertension; however additional studies are needed to
determine if they will become a standard therapy for HF patients.
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Introduction
Since the release of sildenafil, a phosphodiesterase
type 5 (PDE-5) inhibitor, in March 1998, this class of
medicines has become the first line of therapy for
millions of men with erectile dysfunction (ED).
1 In
2003, vardenafil and tadalafil were added to the list
of approved PDE-5 inhibitors. The mechanism of
action of PDE-5 inhibitors is well understood, and
their efficacy in treating ED is well established.
2
However, the role of PDE-5 inhibitors as potential
therapy for other diseases is still under investiga-
tion. The three PDE-5 inhibitors each reduce
endothelial dysfunction.
3–6 As a result of the
endothelial dysfunction that can occur with some
types of ED, links between cardiovascular diseases
and ED have been discovered.
7,8 ED is associated
with coronary artery disease,
9 hypertension
10 and
now heart failure (HF).
11
The goal of this review is to describe the
prevalence of ED in HF patients, causes of ED
specific to patients with HF, the cardiac risk
assessment of sexual activity, the safety of PDE-5
inhibitors to treat ED in HF patients, the efficacy of
PDE-5 inhibitors for ED in HF patients, the hemo-
dynamic effects of PDE-5 inhibitors on HF, the
potential mechanisms by which PDE-5 inhibitors
improve HF and role of PDE-5 inhibitors in
pulmonary hypertension.
Prevalence of ED in patients with HF
The prevalence of HF in the United States is
estimated at 5.3 million by the American Heart
Association.
12 The Massachusetts Male Aging study
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www.nature.com/ijirreported that of healthy men between the ages of 40
and 70 years, approximately 52% had some degree
of ED.
13 Because cardiovascular disease and
ED share similar risk factors, it is not surprising
to find that many patients have both conditions.
It is estimated that 60–89% of HF patients have
some degree of ED.
14–16 One study of 329 HF
patients demonstrated a prevalence of ED that
was 81, 90 and 91% in Hispanic, black and
white men. There was no statistically significant
difference in severity among the three groups.
15
These studies strengthened the link between ED
and HF.
Causes of ED in patients with HF
Table 1 summarizes the causes of ED that are
specific to HF patients. Inadequate exercise capacity
can increase performance anxiety, which further
worsens ED, and may lead to depression. HF, ED and
depression have been described as a triad of
conditions that reciprocally exacerbate each other.
17
Atherosclerosis is a common cause of HF, and its
pathogenesis begins with endothelial dysfunction,
with eventual development of atherosclerotic pla-
ques that obstruct blood flow. The obstruction may
also occur in the arteries that supply the corpus
cavernosum. Thiazide diuretics, digoxin, aldoster-
one and traditional b-blockers have been linked to
ED.
18–21 However some third generation b-blockers
and angiotensin receptor blockers have been asso-
ciated with improvement of ED due to their
protective effects on penile tissue and endothelial
function.
22–25 In summary, causes of ED in
HF patients are decreased exercise capacity, depres-
sion, endothelial dysfunction and standard HF
medications.
Cardiac risk assessment and safety of
sexual activity in HF patients
The Second Princeton Consensus provides guide-
lines for assessing risk for sexual activity in patients
with a cardiac history. Patients are stratified into one
of three groups. Low risk includes asymptomatic
patients with less than three cardiac risk factors,
mild stable angina, more than 6 weeks post-
myocardial infarction, New York Heart Association
(NYHA) class I HF or mild valvular disease.
Intermediate risk includes asymptomatic patients
with more than three cardiac risk factors, moderate
stable angina, between 2 and 6 weeks post-myocar-
dial infarction or NYHA class II HF. High risk
includes unstable angina, uncontrolled hyperten-
sion, NYHA class III or IV HF, less than 2 weeks
post-myocardial infarction or moderate–to-severe
valvular dysfunction. If patients are low risk, then
resuming sexual activity is recommended. If pa-
tients are high risk, then it is recommended that
sexual activity be postponed until the patient is
stabilized. If patients are intermediate risk, assess-
ment with cardiac testing is recommended to allow
restratification into either low or high risk.
26
Studies reporting the clinical and physiological
effects of sexual activity in patients with HF are
sparse. The amount of energy that is involved in
sexual activity from the preorgasmic to orgasmic
phase is approximately 2.0–4.0 metabolic equiva-
lents of the tasks. This is roughly equivalent to doing
easy housework or climbing a flight of stairs.
27 It is
reasonable to think that HF patients who have this
Table 1 Causes of ED in HF patients
Causes Mechanisms
Decreased exercise capacity Impaired increase in stroke volume leads to inadequate cardiac output for exercise or sexual
activity
Psychiatric Performance anxiety secondary to poor exercise tolerance
Depression
Psychiatric medications
Atherosclerosis
Endothelial dysfunction Loss of vasodilation
Increased vasoconstrictors
Atherosclerotic plaques Decreased blood flow to corpus cavernosum
Medications
Thiazide diuretics Mechanism unclear
Digoxin Inhibition of sodium pump activity alters smooth muscle activity in corpus cavernosum tissue
Aldosterone Enhance contractile response of penile corpus cavernosum tissue to norepinephrine
Traditional b-blockers Mechanism unclear
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sexual activity. In a letter to the editor, Cremers
et al.
28 reported the case of a 53-year-old man with
HF and secondary pulmonary hypertension with an
ambulatory hemodynamic monitor. The author
demonstrated that sexual activity affected the heart
differently compared to similar physical exercise.
The patient did not complain of any adverse events
during intercourse, yet had larger increases of right
ventricular systolic pressure, right ventricular dia-
stolic pressure and estimated pulmonary artery
pressure during sexual activity compared to physi-
cal activity of similar metabolic equivalents
achieved by brisk walking. This discrepancy may
have been due to the psychological anticipation and
sympathetic activation associated with sexual activ-
ity or the position of the patient during sexual
activity and physical exercise. Right ventricular
pressures in a supine HF patient may be elevated
compared to a standing patient. This case report
demonstrated that additional studies are needed to
elucidate the physiological effects that sexual
activity has on HF patients.
Efficacy of PDE-5 inhibitors for ED in
patients with HF
Table 2 summarizes studies demonstrating PDE-5
inhibitors’ efficacy for treating ED in patients with
HF. Katz et al.
29 performed a study to determine
sildenafil’s effect in patients with stable chronic HF.
This placebo-controlled, double-blinded study trea-
ted 137 patients with either flexible dosing sildena-
fil or placebo for 12 weeks. Patients were given the
International Index of Erectile Function question-
naire at the start and end of the 12-week study
period. The primary outcomes of the study were the
third question pertaining to the patient’s ability to
achieve penetration and the fourth question pertain-
ing to the patient’s ability to maintain an erection
until the completion of intercourse. The results
showed that there was a statistically significant
improvement on questions 3 and 4. This study
demonstrated that sildenafil was effective in treating
ED in stable HF patients.
Webster et al.
30 performed a placebo-controlled,
double-blinded, crossover study of 35 patients with
NYHA class II and III HF and ED who were treated
with sildenafil. In addition to the International
Index of Erectile Function questionnaire, patient’s
quality of life and mood were assessed with the
Minnesota Living with Heart Failure Questionnaire
and the Beck Depression Index. Patients had a
significant improvement in ED, depression and
quality of life assessed by the questionnaires. Freitas
et al.
31 also performed a study evaluating the
efficacy of sildenafil for ED in HF patients. In their
study, 12 patients with ejection fraction o40%
received sildenafil for 1 month. Patients answered
the International Index of Erectile Function ques-
tionnaire and the Minnesota Living with Heart
Failure Questionnaire before and 1 month after
treatment with sildenafil. Sildenafil caused a sig-
nificant improvement in both erectile function and
quality of life. In summary, studies performed to
date show that the PDE-5 inhibitor sildenafil is
effective in treating ED in patients with HF; whether
the other PDE-5 inhibitors are effective in this
patient cohort remains to be determined.
Safety of PDE-5 inhibitors in HF patients
Common adverse effects of PDE-5 inhibitors are
generally related to either the vasodilatory (for
example, headache or flushing) or gastrointestinal
(for example, dyspepsia or reflux) effects. Less
commonly described adverse affects are visual
complaints (for example, blue-green color tinge or
blurry vision) or myalgias.
32 Nitrates are contra-
indicated during PDE-5 inhibitor use due to hypo-
tension. As sildenafil and vardenafil have
approximately 4h half-lives, nitrates should be
Table 2 Efficacy of treating ED with sildenafil in HF patients
Study n Type of study Length of Tx
(weeks)
IIEF questions
evaluated
Baseline Post Tx p-value
Katz et al.
29 137 Rand, PC, DB 12 Q3 1.7 2.8/3.7 0.0003
*
Q4 1.4 2.4/3.3 0.0012
*
(P/S)
Webster et al.
30 35 Rand, PC, DB, Cross 6 Q1–5, 15 B9 B16 o0.001
w
Freitas et al.
31 12 Prospective 4 IIEF5 9.6 19.3 0.0001
w
Abbreviations: Cross, crossover; DB, double blind; IIEF, International Index of Erectile Function; IIEF5, abbreviated version of IIEF with
5 questions; n, number of patients; P, placebo; PC, placebo control; Q, question; Rand, randomized; S, sildenafil; Tx, treatment.
*Significance between sildenafil and placebo post-treatment values for each question.
wSignificance between post-treatment and baseline values.
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33 Tadalafil has a half-life of
17.5h that prolongs the risk of severe hypotension
with concomitant use of nitrates. Kloner et al.
34
demonstrated that nitrates should be avoided for
48h after tadalafil use. If a patient should develop
hypotension secondary to concomitant use of
nitrates and PDE-5 inhibitors, then treatment
recommended by the American College of Cardio-
logy consensus statement should include placing
the patient in the Trendelenburg position, fluid
administration and possible further blood pressure
support with a-a n db-adrenergic agonists or an
intraaortic balloon pump.
26,32
Patients with HF are not exempt from the above
adverse effects of PDE-5 inhibitors. However, does
the impaired left ventricular function put HF
patients at increased risk for adverse effects with
PDE-5 inhibitors? Katz et al.
29 evaluated the safety of
flexible dosing of sildenafil in 137 HF patients for 12
weeks. Among them, 60% of the treatment group
and 48% of the placebo group developed adverse
events; only 3 and 5%, respectively, were serious
adverse events. Only two patients from each group
discontinued treatment secondary to the adverse
event. In a study by Webster et al.
30 there were no
reports of any adverse effects among 35 HF patients
receiving sildenafil treatment over a 6-week period.
In a study by Freitas et al.
31 only 1 of 12 HF patients
complained of mild headache and visual change
associated with sildenafil treatment over a 4-week
period. These studies demonstrated that it was safe
to treat stable HF patients with sildenafil for their
ED, and that their reduced left ventricular function
did not put them at increased risk for adverse
effects. However, it is important to note that these
patients did not have HF secondary to aortic
stenosis or hypertrophic obstructive cardiomyopa-
thy. Vasodilating medications, including the PDE-5
inhibitors, are generally avoided in patients with
aortic stenosis or hypertrophic obstructive cardio-
myopathy because of a possible increase in outflow
gradient and hypotension.
Effects of PDE-5 inhibitors on HF
Acute studies
Table 3 summarizes the short-term effects of PDE-5
inhibitors on HF. Bocchi et al.
35 performed a double-
blind, placebo-controlled, crossover study that eval-
uated sildenafil’s effect on exercise and neurohor-
monal activation in patients with HF. A total of 23
men with HF were given either placebo or 50mg of
sildenafil approximately 1h before a 6min tread-
mill-walking test and a maximal exercise stress test
on day 1, and then crossed over to the other
medicine before exercise testing on the next day.
Hemodynamics were recorded for each group and
compared. Sildenafil reduced basal heart rate and
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International Journal of Impotence Researchsystolic and diastolic blood pressure. The heart rate
throughout the 6min treadmill-walking test was
also significantly decreased by sildenafil. The peak
oxygen consumption at maximal exercise and
exercise time were significantly increased and the
ventilation to carbon dioxide production slope was
significantly decreased during peak exercise tread-
mill. The study concluded that the decrease in the
heart rate during exercise observed with sildenafil
could reduce the myocardial oxygen demand and
lead to less ischemia.
Hirata et al.
36 studied the effects of sildenafil on
cardiac function in HF patients. Twenty patients
with ejection fraction o35% were studied in a
double-blind, placebo-controlled, crossover study.
Cardiac output was measured with echocardio-
graphy after either 50mg of sildenafil or placebo.
Sildenafil increased cardiac index by approximately
16% and decreased total systemic vascular resis-
tance (SVR). The study concluded that patients with
HF on sildenafil might have an increase in exercise
tolerance because of a decrease in SVR and reduced
afterload leading to an increase in cardiac index.
Katz et al.
3 performed a study evaluating the effect
of various doses of sildenafil on flow-mediated
vasodilation in HF patients. This randomized,
double-blind study analyzed the brachial artery
flow-mediated vasodilation after 1, 3 and 5min of
occlusion (cuff inflation) at baseline and 1h after an
oral dose of either 12.5, 25 or 50mg of sildenafil or
placebo. There was a statistically significant in-
crease in percentage of vasodilation in the 25mg
(3.3±1.9, 3.8±1.8 and 4.0±1.8% at 1, 3 and 5min,
respectively) and 50mg (3.7±1.3, 4.1±1.1 and
3.9±1.3%, respectively) sildenafil groups compared
to placebo (0.7±1.1, 0.2±1.2 and 0.6±0.8%, res-
pectively) at all time intervals. This improvement of
flow-mediated vasodilation is consistent with the
decrease in SVR described by Hirata et al.
36 and
shows that sildenafil’s ability to improve endo-
thelial dysfunction extends to patients with HF.
Lewis et al.
37 performed a study on the acute
effects of sildenafil on HF patients. Thirteen patients
with NYHA class III HF underwent invasive right
heart hemodynamic monitoring, cardiopulmonary
exercise testing and radionuclide ventriculography
before and 1h after 50mg of sildenafil. Sildenafil
significantly decreased resting mean pulmonary
artery pressure, pulmonary vascular resistance
(PVR), SVR and increased cardiac index. Also,
sildenafil significantly decreased exercise mean
pulmonary artery pressure, PVR, PVR/SVR ratio
and increased exercise cardiac index. The hemody-
namics improved without significant changes in
resting or exercise mean arterial pressure, resting
heart rate or pulmonary capillary wedge pressure.
Sildenafil also increased peak oxygen consumption
at maximal exercise and decreased the ventilation to
carbon dioxide production slope. When the patients
were stratified to either having pulmonary hyper-
tension (defined as a resting pulmonary artery
pressure 425mmHg) or not, the hemodynamic
effects were predominantly observed in the patients
with pulmonary hypertension. There was a statisti-
cally significant rise in rest and exercise right
ventricular ejection fraction after treatment
with sildenafil in patients with pulmonary hyper-
tension. The authors concluded that sildenafil’s
effects on patients with HF are mainly due to an
improved pulmonary artery pressure, and may be of
benefit to HF patients with secondary pulmonary
hypertension.
Al-Hesayen et al.
38 evaluated the effects of
intravenous sildenafil on hemodynamics and sym-
pathetic activity in HF patients. Ten patients
received intravenous sildenafil and had right heart
catheterizations and norepinephrine spillover rates
calculated. There was a significant reduction in
right atrial pressure, mean pulmonary artery pres-
sure, mean arterial pressure and PVR/SVR ratio,
with a significant increase in cardiac index. Also,
there was a significant reduction in cardiac norepi-
nephrine spillover. The study concluded that silde-
nafil acutely reduced pulmonary artery pressure
without increasing cardiac sympathetic activity.
These studies show PDE-5 inhibition in HF leads
to improved endothelial function, as well as de-
creased pulmonary artery pressure and improved
cardiac index.
Long-term studies
The following studies revealed PDE-5 inhibitor’s
effect in longer-term studies (Table 3). Behling
et al.
39 performed a study that analyzed the effects
of sildenafil treatment for 4 weeks in HF patients.
This double-blind, placebo-controlled study in-
cluded 19 patients with HF who were randomized
to placebo or 50mg of sildenafil three times daily.
Patients underwent cardiopulmonary exercise test-
ing and echocardiography at baseline and after 4
weeks of therapy. Sildenafil caused a significant
improvement in oxygen consumption and a de-
crease in the ventilation to carbon dioxide produc-
tion slope and echocardiography-derived systolic
pulmonary artery pressure after 4 weeks of treat-
ment. The study concluded that with 4 weeks of
PDE-5 inhibitor therapy, patients with HF had
improved exercise capacity and reduced pulmonary
hypertension.
Guazzi et al.
40 evaluated the effects of sildenafil
over 6 months in patients with HF. A total of 46
patients were randomized to placebo or 50mg of
sildenafil three times daily and had recorded
measurements of flow-mediated vasodilation and
cardiopulmonary exercise testing at baseline, 3 and
6 months. Sildenafil increased peak oxygen con-
sumption and flow-mediated vasodilation with
significant decreases in systolic pulmonary artery
PDE-5 inhibitors and heart failure
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International Journal of Impotence Researchpressure and ventilation to carbon dioxide produc-
tion slope. No serious adverse events were recorded.
Three patients complained of flushing during the
6-month period. The authors concluded that chronic
sildenafil was safe to administer to HF patients and
would also improve pulmonary hypertension and
exercise tolerance leading to an improved quality
of life.
Lewis et al.
41 examined the effects of sildenafil in
HF patients with secondary pulmonary hyperten-
sion. In this double-blind study, 34 patients with
pulmonary artery pressure 425mmHg were rando-
mized to either placebo or sildenafil, with a starting
dose of 25mg and titrated up to a maximum dose of
75mg three times daily. Before starting either
sildenafil or placebo, patients performed cardiopul-
monary exercise testing with concurrent hemody-
namic monitoring, radionuclide ventriculography
and Minnesota Living with Heart Failure Question-
naire. These tests were repeated after 12 weeks of
therapy. Sildenafil significantly increased the peak
oxygen consumption, 6min walking distance, peak
exercise cardiac output, and stroke volume; and
significantly decreased resting and exercise PVR
and PVR to SVR ratio. These parameters occurred
without a significant change in heart rate, arterial
pressure, pulmonary artery pressure, pulmonary
capillary wedge pressure, or cardiac index. The
patients who received sildenafil also showed a
significant improvement in right ventricular ejection
fraction and Minnesota Living with Heart Failure
Questionnaire as compared to placebo. The authors
concluded that PDE-5 inhibitors provide an innova-
tive approach to treating HF patients with secondary
pulmonary hypertension.
The above studies demonstrated the beneficial
cardiopulmonary effects of sildenafil in patients
with HF (Table 3). Whether these benefits persist for
more than 1 year remains to be determined. In
addition, there is a lack of data in the literature
regarding the effect of vardenafil or tadalafil in HF
patients. Future studies should include all three
PDE-5 inhibitors as well as determine the effect of
the PDE-5 inhibitors on major adverse cardiac
events and mortality. This may be accomplished
with a long-term survival study of patients with HF
randomized to standard HF therapy and placebo
versus standard HF therapy plus a PDE-5 inhibitor.
Mechanisms of PDE-5 inhibitors improving
HF
The exact mechanism(s) by which PDE-5 inhibitors
improve HF are unknown. Several possibilities have
been described in the literature. Studies show that
PDE-5 inhibitors improve endothelial dysfunction
in HF patients. Better endothelial function leads to
improved vasodilatory response of the vasculature
to endogenous nitric oxide, which overcomes nitric
oxide resistance and tolerance seen in HF patients.
42
Better arterial vasodilation leads to improved after-
load reduction, which allows improved forward
stroke volume leading to an increased cardiac
output. Better preload reduction by venous dilation
leads to reduced venous and pulmonary congestion
with decreased right ventricular pressures. Preload
and afterload reduction individually lead to a
decrease in myocardial wall stress, which lowers
myocardial oxygen demand.
43,44
There has been debate in the literature regarding
whether PDE-5 is present in the myocardial cell.
Wallis et al.
45 revealed that PDE-5 was not found in
the cytosol of human myocardial cells and that
sildenafil had no effect on the contractility of the
trabeculae carneae of dogs. However, Nagendran
et al.
46 showed that PDE-5 is upregulated in the
myocardial cells of human hypertrophied right
ventricles from patients with primary pulmonary
hypertension, congenital heart disease or rheumatic
valve disease. The authors also showed that PDE-5
inhibition with sildenafil led to a statistically
significant increase in contractility in a modified
right ventricular Langendorff preparation. The rise
in right ventricular contractility was due to an
intrinsic myocardial effect because the pulmonary
arteries were no longer present and could therefore
not contribute to reduced right ventricular afterload.
Pokreisz et al.
47 confirmed that PDE-5 expression is
greater in left ventricular myocardium of patients
with HF compared to controls. To determine the
impact of elevated PDE-5 levels in diseased left
ventricles, the authors compared the effect of a
myocardial infarction on mice with increased PDE-5
expression versus wild type. The study showed that
left ventricular end-systolic and end-diastolic vo-
lumes were significantly larger in the mice with
PDE-5 overexpression compared to the wild-type
mice 10 weeks after myocardial infarction, which
suggested adverse left ventricular remodeling due to
PDE-5.
Cardiac hypertrophy occurs when the myocar-
dium is challenged with elevated wall stress.
Borlaug et al.
48 demonstrated in 35 randomized,
double-blinded, placebo-controlled healthy male
volunteers that sildenafil dampened the acute
myocardial response to dobutamine. Inhibiting
adrenergic stimulation of the myocardium inhibits
myocardial hypertrophy; inhibiting hypertrophy
may improve HF. In a study by Takimoto et al.,
49
mice underwent transaortic constriction to induce
pressure overload in the heart. Some mice were
treated with either placebo or sildenafil immediately
after surgery for 9 weeks. Another group of mice
were treated 1 week after surgery with either
placebo or sildenafil for 2 weeks. Mice that began
receiving sildenafil immediately after surgery had
significantly less hypertrophy and chamber remo-
deling compared to controls suggesting that silde-
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The mice that received sildenafil 1 week after
surgery showed a gradual decline in the left
ventricular wall mass, thickness and fractional
shortening revealing that sildenafil can reverse
established hypertrophy. Proposed mechanism for
the effect on hypertrophy is that increases in
intramyocardial guanosine 30,50-cyclic monopho-
sphate lead to inhibition of hypertrophy-causing
signaling pathways.
In summary, the mechanism by which PDE-5
inhibitors improve HF may be multifactorial. Stu-
dies revealed that sildenafil has similar effects on
preload and afterload as classic HF medications.
Also PDE-5 inhibitors appear to have an intrinsic
effect on diseased myocardium by increasing con-
tractility as well as inhibiting and even reversing
cardiac hypertrophy.
Role of PDE-5 inhibitors in pulmonary
hypertension
The role of PDE-5 inhibitors for the treatment of
pulmonary hypertension has been established. Galie `
et al.
50 completed a double-blind, placebo-con-
trolled, multicenter, randomized study comparing
the effect of various doses of sildenafil versus placebo
on the 6min walk, mean pulmonary artery pressure
and World Health Organization functional class in
patients with pulmonary hypertension. The causes of
the pulmonary hypertension in this study population
were either repaired congenital shunt, connective-
tissue disease or idiopathic. Pulmonary hypertension
was defined as a mean pulmonary artery pressure
425mmHg and a pulmonary capillary wedge pres-
sure of o15mmHg. After 12 weeks of treatment there
were significant increases in the distance walked in
6min, significant decreases in mean pulmonary
artery pressure and significant improvement in the
World Health Organization functional class at all
three dose levels of sildenafil when compared to
placebo. Patients who completed the 12 weeks were
offered the opportunity to enroll in an extension
study. The 6min walk test was repeated after 1 year
of treatment and the exercise capacity was sustained.
The study concluded that sildenafil is effective and
safe for treating pulmonary hypertension. Sildenafil
was approved by the Food and Drug Administration
for the treatment of pulmonary hypertension in the
form of Revatio (sildenafil citrate; Pfizer, New York,
NY, USA) 20mg three times daily.
Table 4 summarizes the studies evaluating the
effects of the other PDE-5 inhibitors on pulmonary
hypertension. Ghofrani et al.
51 demonstrated the
importance of studying each drug’s specific effect on
cardiovascular diseases, given their differences on
various hemodynamic parameters. Aizawa et al.
52
confirmed Ghofrani et al.’s
51 finding that vardenafil
is not specific to the pulmonary vasculature in the
acute setting, but with chronic treatment, only the
pulmonary artery pressure and PVR were decreased.
The case studies have demonstrated the potential
role of tadalafil in patients with severe pulmonary
hypertension.
53,54
Summary
The PDE-5 inhibitors have revolutionized the treat-
ment of ED; however their role in the treatment of
cardiovascular diseases has yet to be determined. It
is important that clinicians understand that ED is
very common in the HF population, and therefore
physicians should ask their patients about ED. PDE-
5 inhibitors are safe and effective therapy for ED in
patients with mild to moderate HF and who are at
low cardiac risk. PDE-5 inhibitors should be used
with caution in cases of intermediate risk, and
should be avoided in patients with high risk or are
concurrently being treated with nitrates. Sildenafil
is effective in improving the quality of life, exercise
Table 4 Additional PDE-5 inhibitor and pulmonary hypertension studies
Study Findings
Ghofrani et al.
51 Each PDE-5 inhibitor has different acute effects on patients with pulmonary hypertension. All three reduced PVR,
yet only sildenafil and tadalafil reduced PVR/SVR ratio.
Aizawa et al.
52 Vardenafil decreased both PVR and SVR acutely; chronic treatment reduced PVR/SVR ratio in patients with
pulmonary hypertension, suggesting a greater effect on PVR.
Affuso et al.
53 Case report of an idiopathic pulmonary hypertension patient treated with 20mg of tadalafil every other day for 6
months who had a drop in pulmonary artery pressure from 100 to 76mmHg.
Singh et al.
54 Two case reports: a patient with idiopathic pulmonary hypertension treated with 30mg of tadalafil daily for 3
months had a decrease in pulmonary artery pressure from 131 to 92mmHg. A patient with Eisenmenger’s disease
treated with 20mg of tadalafil daily for 3 months had a decrease in pulmonary artery pressure from 130 to
85mmHg.
Abbreviations: PDE-5, phosphodiesterase type 5; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.
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cially patients with pulmonary hypertension. How-
ever whether the other PDE-5 inhibitors have this
same benefit remains to be determined. Studies have
shown that it is safe to treat HF patients with
sildenafil in a chronic setting; however whether
PDE-5 inhibitors decrease mortality or major adverse
cardiac events has not been established. The exact
mechanism by which PDE-5 inhibitors improve HF
is unknown but may be related to improved
endothelial function, reduced preload, reduced
afterload or some direct effect on the diseased
myocardium. Studies have shown that sildenafil is
effective in treating pulmonary hypertension, but
sildenafil’s effect on mortality in these patients also
is unknown. Each of the PDE-5 inhibitors may affect
the hemodynamics of pulmonary hypertension in a
different manner.
Recommendations
For patients with mild to intermediate HF who do
not require nitrate therapy and have ED, it is safe
and effective to treat the ED with PDE-5 inhibitors
(excluding patients with hypertrophic obstructive
cardiomyopathy or aortic stenosis). Patients with
severe HF should avoid treatment with PDE-5
inhibitors until the HF is improved. Currently the
only PDE-5 inhibitor that is approved for pulmonary
hypertension is sildenafil. Further studies are
necessary to determine if tadalafil or vardenafil
improve exercise capacity, functional class and
hemodynamics as well as sildenafil in patients with
pulmonary hypertension. Although the data cur-
rently suggest that PDE-5 inhibitors can improve
hemodynamics, exercise capacity and functional
class in HF patients, additional studies are needed
to determine if PDE-5 inhibitors should be a
standard part of HF therapy.
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